Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 9:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: treprostinil inhalations Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers

NCT03464864
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Sep 1, 2026, 9:32 PM EDT
Recruiting No phase listed Observational

An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

NCT06129240
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease
Interventions
LIQ861
Drug
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
23
States / cities
Phoenix, Arizona • Fresno, California • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 1, 2026, 9:32 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

NCT05649748
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Palmitil, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 1, 2026, 9:32 PM EDT
Recruiting Phase 3 Interventional

An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07234032
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Treprostinil Palmitil Inhalation Powder, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Naples, Florida • Bend, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 1, 2026, 9:32 PM EDT
Completed Phase 4 Interventional Results available

Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication

NCT01268553
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Tucson, Arizona • San Francisco, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Sep 1, 2026, 9:32 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

NCT02630316
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
Interventions
Inhaled Treprostinil, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
96
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 1, 2026, 9:32 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years

NCT02276872
View directory record Official record
Conditions
PAH
Interventions
oral treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
7 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
9
States / cities
Palo Alto, California • San Francisco, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 1, 2026, 9:32 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

NCT07643155
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Treprostinil Palmitil Inhalation Powder
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Lake Forest, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 1, 2026, 9:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants

NCT06091579
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Treprostinil Palmitil Inhalation Powder, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Sep 1, 2026, 9:32 PM EDT
Enrolling by invitation Phase 3 Interventional

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

NCT04905693
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis
Interventions
Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
Drug · Device
Lead sponsor
United Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
1,850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
84
States / cities
Birmingham, Alabama • Franklin, Arizona • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 1, 2026, 9:32 PM EDT
Terminated Phase 2 Interventional Results available

Treprostinil Sodium Inhalation for Patients At High Risk for ARDS

NCT02370095
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Treprostinil Inhalation Solution, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 1, 2026, 9:32 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension

NCT02471183
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Selexipag
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
La Jolla, California • San Francisco, California • Torrance, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 1, 2026, 9:32 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

NCT07481981
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Palmitil Inhalation Powder, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Santa Barbara, California • Anderson, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 1, 2026, 9:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants

NCT06193031
View directory record Official record
Conditions
Healthy Volunteers
Interventions
C16TR, Placebo, Tyvaso®
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 1, 2026, 9:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy Participants

NCT07102316
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TPIP F2, TPIP F3
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 1, 2026, 9:32 PM EDT
Completed Phase 1 Interventional

Treatment of Pulmonary Hypertension Associated COPD With Inhaled Treprostinil-1

NCT01758744
View directory record Official record
Conditions
Pulmonary Hypertension, COPD
Interventions
Inhaled Treprostinil Therapy
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Aurora, Colorado • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Sep 1, 2026, 9:32 PM EDT
Terminated Phase 2 Interventional Results available

Acute Effects of Inhaled Treprostinil in Fontan Patients

NCT02769624
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Treprostinil, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Sep 1, 2026, 9:32 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)

NCT04791514
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Palmitil
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Sep 1, 2026, 9:32 PM EDT
Recruiting No phase listed Observational

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT06388421
View directory record Official record
Conditions
Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
Interventions
Prospective study assessments
Other
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
70
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 1, 2026, 9:32 PM EDT
Terminated Phase 3 Interventional Results available

Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)

NCT03794583
View directory record Official record
Conditions
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
Inhaled treprostinil solution
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
28
States / cities
Birmingham, Alabama • Sacramento, California • Clearwater, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 1, 2026, 9:32 PM EDT
Recruiting Phase 3 Interventional

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

NCT05943535
View directory record Official record
Conditions
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Interventions
Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
Drug · Device
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 1, 2026, 9:32 PM EDT
Completed Phase 1 Interventional Results available

Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso

NCT03950739
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Inhalation Powder
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Sep 1, 2026, 9:32 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD

NCT04691154
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Lung Diseases
Interventions
L606 inhalation suspension
Combination Product
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
8
States / cities
Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 1, 2026, 9:32 PM EDT
Terminated No phase listed Observational

Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching

NCT01494896
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Jacksonville, Florida • Weston, Florida
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Sep 1, 2026, 9:32 PM EDT